Deficient butyrate-producing capacity in the gut microbiome is associated with bacterial network disturbances and fatigue symptoms in ME/CFS. — ME/CFS Atlas
E2 ModerateModerate confidencePEM not requiredObservationalPeer-reviewedReviewed
Standard · 3 min
Deficient butyrate-producing capacity in the gut microbiome is associated with bacterial network disturbances and fatigue symptoms in ME/CFS.
Guo, Cheng, Che, Xiaoyu, Briese, Thomas et al. · Cell host & microbe · 2023 · DOI
Quick Summary
Researchers studied gut bacteria in people with ME/CFS and found that they have fewer healthy bacteria that produce a substance called butyrate, which normally helps protect the gut and reduce inflammation. The bacteria that are missing—Faecalibacterium prausnitzii and Eubacterium rectale—are known to be beneficial in healthy people. Importantly, people with more of these bacteria had less severe fatigue, suggesting a connection between gut bacteria health and ME/CFS symptoms.
Why It Matters
This study provides concrete evidence that ME/CFS involves measurable changes in gut bacteria and their function, potentially opening new avenues for diagnosis and treatment. The identification of specific bacterial deficiencies offers targets for future therapeutic interventions, such as probiotics or dietary modifications, that could help restore healthy gut function and reduce fatigue in ME/CFS patients.
Observed Findings
Faecalibacterium prausnitzii and Eubacterium rectale are significantly reduced in ME/CFS patients compared to healthy controls.
Fecal butyrate concentrations and microbial butyrate synthesis capacity are decreased in ME/CFS.
Abundance of Faecalibacterium prausnitzii is inversely associated with fatigue severity.
Microbiome-based machine learning classifiers distinguish ME/CFS from controls across geographically diverse populations.
Gut microbiome network interactions are disturbed in ME/CFS patients.
Inferred Conclusions
ME/CFS involves functional gut dysbiosis with specific deficiency in butyrate-producing bacteria capacity.
Microbiome alterations are consistent enough across populations to serve as potential biomarkers for disease classification.
Restoration of butyrate-producing bacteria represents a plausible therapeutic target for ME/CFS management.
The gut dysbiosis in ME/CFS reflects more than simple loss of bacteria—it represents organized network disturbance with functional consequences.
Remaining Questions
Does restoring these bacteria or butyrate levels improve ME/CFS symptoms and fatigue severity in clinical trials?
What This Study Does Not Prove
This study does not prove that deficient butyrate production causes ME/CFS—it only shows an association. It does not establish whether restoring these bacteria would improve symptoms, nor does it explain the mechanisms by which altered butyrate levels might contribute to fatigue, cognitive dysfunction, or other ME/CFS symptoms. The cross-sectional design means the temporal relationship between microbiome changes and disease onset cannot be determined.
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Contribute
Private, reviewed by a human. Not a public comment thread.
What factors drive the initial loss or dysfunction of these butyrate-producing bacteria in ME/CFS patients?
How does reduced butyrate production mechanistically contribute to ME/CFS symptoms including fatigue, cognitive dysfunction, and gastrointestinal disturbances?
Can longitudinal studies determine whether microbiome changes precede ME/CFS onset or result from disease-related lifestyle and dietary changes?